243 related articles for article (PubMed ID: 11027594)
1. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
[TBL] [Abstract][Full Text] [Related]
2. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
[TBL] [Abstract][Full Text] [Related]
3. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
[TBL] [Abstract][Full Text] [Related]
4. Study of the peptide length and amino acid specific substitution in the antigenic activity of the chimeric synthetic peptides, containing the p19 core and gp46 envelope proteins of the HTLV-I virus.
Marin MH; Rodríguez-Tanty C; Higginson-Clarke D; Bocalandro YM; Peña LP
Biochem Biophys Res Commun; 2005 Oct; 336(3):983-6. PubMed ID: 16157308
[TBL] [Abstract][Full Text] [Related]
5. Use of a chimeric synthetic peptide from the core p19 protein and the envelope gp46 glycoprotein in the immunodiagnosis of HTLV-II virus infection.
Hernández Marin M; Márquez Bocalandro Y; Vallejo RV; Rodríguez Tanty C; Higginson Clark D; Pozo Peña L; Silva León C
Prep Biochem Biotechnol; 2003 Feb; 33(1):29-38. PubMed ID: 12693813
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
[TBL] [Abstract][Full Text] [Related]
7. Development and Evaluation of a Novel ELISA for Detection of Antibodies against HTLV-I Using Chimeric Peptides.
Mosadeghi P; Heydari-Zarnagh H
Iran J Allergy Asthma Immunol; 2018 Apr; 17(2):144-150. PubMed ID: 29757587
[TBL] [Abstract][Full Text] [Related]
8. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
[TBL] [Abstract][Full Text] [Related]
9. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of immunodominant epitopes of human T-lymphotropic virus type 1 (HTLV-I) using synthetic peptides.
Lairmore MD; Lal RB; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):117-22. PubMed ID: 9346842
[TBL] [Abstract][Full Text] [Related]
11. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
12. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
[TBL] [Abstract][Full Text] [Related]
13. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
[TBL] [Abstract][Full Text] [Related]
14. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
[TBL] [Abstract][Full Text] [Related]
15. [Identification of immunoreactive epitopes in proteins coded by gag, env, and pol genes of the type I human T-lymphotropic virus (HTLV-I) using synthetic peptides].
Iaroslavtseva NG; Ivanov VS; Grebennikova ZhO; Kornilaeva GV; Pashkova TA; Chikin LD; Ostrovskiĭ AG; Andreev SM; Khaitov RM; Karamov EV
Bioorg Khim; 1995 Oct; 21(10):752-60. PubMed ID: 8573207
[TBL] [Abstract][Full Text] [Related]
16. Chimeric synthetic peptides from the nucleocapsid p24 protein of human immunodeficiency virus type-1.
Hernández M; Rodríguez I; Pozo L; Rivero J
Biochem Biophys Res Commun; 2001 Mar; 282(1):1-3. PubMed ID: 11263961
[TBL] [Abstract][Full Text] [Related]
17. [Immunoreactivity of synthetic peptides, corresponding to B-cellular epitopes of human type I T-lymphotrophic virus structural proteins].
Rasuli AM; Klepikov NN; Andreev SM; Sidorova MV; Vafina MG; Seniuta NB; Pavlish OA; Syrtsev AV; Gurtsevich VE
Mol Biol (Mosk); 1993; 27(4):880-7. PubMed ID: 8361494
[TBL] [Abstract][Full Text] [Related]
18. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
[TBL] [Abstract][Full Text] [Related]
19. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
[TBL] [Abstract][Full Text] [Related]
20. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
Arp J; LeVatte M; Rowe J; Perkins S; King E; Leystra-Lantz C; Foung SK; Dekaban GA
J Virol; 1996 Nov; 70(11):7349-59. PubMed ID: 8892853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
